Open in web browser

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

Biosimilars

[BLOG]: 5 reasons biosimilars must have distinguishable names

By Louis Tharp
There are 5 simple reasons why biosimilars must be given distinguishable names and made available only under transparent circumstances. The need for guidance is urgent

5 reasons to keep biosimilar names the same

By Tracey Walker
Should biosimilars use the same International Nonproprietary Name (INN)? Here are 5 reasons why the answer is "yes"

CONTINUING EDUCATION

MTM essentials for COPD Management: Part 2

This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in understanding strategies for improving patient outcomes related to COPD management.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT32-KZV23.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
To review you registration page to ensure the data is up to date, or to register, go
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Rheumatoid arthritis drug may benefit atopic dermatitis patients

By Tracey Walker
Patients with moderate to severe atopic dermatitis (AD)—or eczema—may be successfully treated using a rheumatoid arthritis (RA) drug recently shown to reverse 2 other skin conditions, vitiligo and alopecia areata, according to a new study. What Yale researchers found

July 27, 2015

Related Articles

Patient groups bothered over diminished safety standards for biosimilars

Biosimilars need better labeling: Physicians

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click here to contact Editorial. Sales, Reprints, Classified questions? Click here to contact the Sales Team.

ModernMedicine logo
UBM  logo

UBM MEDICA